Publications by authors named "Alexander C Egilman"

Claim this Profile
S
Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling Drugs.
Alexander C Egilman, Aaron S Kesselheim, Benjamin N Rome

Health Serv Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of first generic drugs approved through "skinny labeling," 2021 to 2023.
Therese J Ziaks, Chukwubuikem M Akanegbu, Alexander C Egilman, Aaron S Kesselheim

J Manag Care Spec Pharm· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Benefit of Top-Selling Oncology Drugs in Medicare.
Stephanie Wang, Alexander C Egilman, Georg Hahn, Aaron S Kesselheim

JAMA Netw Open· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
Alexander C Egilman, Aaron S Kesselheim, Ameet Sarpatwari, Benjamin N Rome

Ann Intern Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Federal Trade Commission Actions on Prescription Drugs, 2000-2022.
C Joseph Ross Daval, Alexander C Egilman, Ameet Sarpatwari, Aaron S Kesselheim

JAMA· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis.
Alexander C Egilman, Aaron S Kesselheim, Jerry Avorn, Adam J N Raymakers, Benjamin N Rome

JAMA Dermatol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gauging the Value of Top-Selling Drugs in Medicare-Reply.
Alexander C Egilman, Benjamin N Rome, Aaron S Kesselheim

JAMA· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
Alexander C Egilman, Benjamin N Rome, Aaron S Kesselheim

JAMA· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone.
Benjamin N Rome, Alexander C Egilman, Neeraj G Patel, Aaron S Kesselheim

Value Health· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.
Alexander C Egilman, Victor L Van de Wiele, Benjamin N Rome, Jonathan J Darrow, S Sean Tu

JAMA Intern Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated Medicare Part B Savings From Inflationary Rebates.
Alexander C Egilman, Aaron S Kesselheim, Benjamin N Rome

JAMA· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Benjamin N Rome, Sarosh Nagar, Alexander C Egilman, Junyi Wang, William B Feldman

JAMA Health Forum· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Trends in Prescription Drug Launch Prices-Reply.
Benjamin N Rome, Alexander C Egilman, Aaron S Kesselheim

JAMA· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early experience with the FDA's regulatory review of novel gene therapies.
Jeremy Puthumana, Alexander C Egilman, Reshma Ramachandran, Nida Naushad, Nilay Shah

BMJ Evid Based Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in Prescription Drug Launch Prices, 2008-2021.
Benjamin N Rome, Alexander C Egilman, Aaron S Kesselheim

JAMA· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Joshua J Skydel, Alexander C Egilman, Joshua D Wallach, Reshma Ramachandran, Ravi Gupta

JAMA Health Forum· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020.
Audrey D Zhang, Jeremy Puthumana, Alexander C Egilman, Jason L Schwartz, Joseph S Ross

J Gen Intern Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration.
Alexander C Egilman, Amy Kapczynski, Margaret E McCarthy, Anita T Luxkaranayagam, Christopher J Morten

J Law Med Ethics· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Alexander C Egilman, Joseph S Ross, Matthew Herder

CMAJ· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the data available via Health Canada's clinical information portal.
Alexander C Egilman, Joseph S Ross, Matthew Herder

CMAJ· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review.
Aaron S Long, Audrey D Zhang, Caitlin E Meyer, Alexander C Egilman, Joseph S Ross

JAMA Netw Open· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration.
Jeremy Puthumana, Alexander C Egilman, Audrey D Zhang, Jason L Schwartz, Joseph S Ross

JAMA Intern Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease.
Joshua D Wallach, Stylianos Serghiou, Lingzhi Chu, Alexander C Egilman, Vasilis Vasiliou

BMC Med Res Methodol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Digital medicine systems: an evergreening strategy or an advance in medication management?
Alexander C Egilman, Joseph S Ross

BMJ Evid Based Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017.
Alexander C Egilman, Joshua D Wallach, Christopher J Morten, Peter Lurie, Joseph S Ross

Res Integr Peer Rev· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis